Literature DB >> 17410387

In vitro susceptibility of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium to daptomycin and other antibiotics.

Z Samra1, O Ofir, H Shmuely.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17410387     DOI： 10.1007/s10096-007-0288-2

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   5.103


× No keyword cloud information.
  9 in total

1.  Correlation of MIC methods and tentative interpretive criteria for disk diffusion susceptibility testing using NCCLS methodology for fusidic acid.

Authors:  R Skov; N Frimodt-Møller; F Espersen
Journal:  Diagn Microbiol Infect Dis       Date:  2001-07       Impact factor: 2.803

2.  Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium.

Authors:  Inmaculada A Herrero; Nicolas C Issa; Robin Patel
Journal:  N Engl J Med       Date:  2002-03-14       Impact factor: 91.245

3.  In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals.

Authors:  Olivier Denis; Ariane Deplano; Claire Nonhoff; Marie Hallin; Raf De Ryck; Raymond Vanhoof; Ricardo De Mendonça; Marc J Struelens
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

4.  Susceptibility of methicillin-resistant Staphylococcus aureus to vancomycin, teicoplanin, linezolid, pristinamycin and other antibiotics.

Authors:  Zmira Samra; Orit Ofer; Haim Shmuely
Journal:  Isr Med Assoc J       Date:  2005-03       Impact factor: 0.892

5.  Multicenter evaluation of the Etest and disk diffusion methods for differentiating daptomycin-susceptible from non-daptomycin-susceptible Staphylococcus aureus isolates.

Authors:  Laura A Jevitt; Grace M Thorne; Maria M Traczewski; Ronald N Jones; John E McGowan; Fred C Tenover; Steven D Brown
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

Review 6.  The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria.

Authors:  M J Rybak
Journal:  Clin Microbiol Infect       Date:  2006-03       Impact factor: 8.067

7.  In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.

Authors:  Laura A Jevitt; Amanda J Smith; Portia P Williams; Patti M Raney; John E McGowan; Fred C Tenover
Journal:  Microb Drug Resist       Date:  2003       Impact factor: 3.431

8.  High percentage of methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to glycopeptides in The Netherlands.

Authors:  Arjanne Van Griethuysen; Annemarie Van 't Veen; Anton Buiting; Timothy Walsh; Jan Kluytmans
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

9.  Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms.

Authors:  Jennifer M Streit; Ronald N Jones; Helio S Sader
Journal:  J Antimicrob Chemother       Date:  2004-02-25       Impact factor: 5.790
  9 in total
  3 in total

1.  Peptide nucleic acid fluorescent in situ hybridization for hospital-acquired enterococcal bacteremia: delivering earlier effective antimicrobial therapy.

Authors:  Graeme N Forrest; Mary-Claire Roghmann; Latoya S Toombs; Jennifer K Johnson; Elizabeth Weekes; Durry P Lincalis; Richard A Venezia
Journal:  Antimicrob Agents Chemother       Date:  2008-07-28       Impact factor: 5.191

Review 2.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

Review 3.  Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia.

Authors:  Philip I Hair; Susan J Keam
Journal:  Drugs       Date:  2007       Impact factor: 9.546
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.